SpyGlass Pharma
SGP
24.30
+0.40
+1.67%
SpyGlass Pharma
US · SGP
#3415 by market cap
Listed 2026
24.30
+0.40
+1.67%
Live - 5344 symbols - heartbeat 274s ago
· 2026-10-08 10:03
After-hours
23.90
0.00%
- Market cap
- 812.79M
- P/E (TTM)i
- -14.50
- P/Bi
- 3.50
- EPSi
- -1.19
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on SGP?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 3 years
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | -- | -- | -- |
| Gross profit | -- | -- | -- |
| Selling & admin expenses | 4.27M | 7.08M | 12.27M |
| Research & development | 9.96M | 19.98M | 29.18M |
| Operating profit | -14.23M | -27.06M | -41.45M |
| Pretax profit | -13.32M | -29.16M | -39.87M |
| Tax | 0 | 0 | 0 |
| Net profit | -13.32M | -29.16M | -39.87M |
| Basic EPS | -1 | -2 | -1 |
| Diluted EPS | -1.17 | -1.62 | -1.25 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.37M | 1.96M | 3.01M | 5.92M | 6.87M | 11.03M |
| Research & development | 6.05M | 7.33M | 8.09M | 7.71M | 8.54M | 10.94M |
| Operating profit | -7.42M | -9.30M | -11.10M | -13.63M | -15.41M | -21.97M |
| Pretax profit | -8.82M | -8.68M | -9.82M | -12.56M | -13.82M | -19.86M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -8.82M | -8.68M | -9.82M | -12.56M | -13.82M | -19.86M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | -1 |
| Diluted EPS | -0.49 | -0.27 | -0.31 | -0.39 | -0.69 | -0.59 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 40.61M | 17.41M | 108.77M |
| Cash & ST investments | 40.32M | 16.27M | 107.44M |
| Inventory | -- | -- | -- |
| Total assets | 41.15M | 23.32M | 115.87M |
| Total current liabilities | 1.59M | 7.79M | 8.58M |
| Short-term debt | -- | 442.00K | -- |
| Long-term debt | -- | -- | -- |
| Total liabilities | 74,134,984.00 | 83,792,000.00 | 214,703,000.00 |
| Total equity | -32.99M | -60.47M | -98.84M |
| Retained earnings | -35.70M | -64.86M | -104.73M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 119.70M | 108.77M | 253.36M | 236.46M |
| Cash & ST investments | -- | -- | 118.04M | 107.44M | 251.00M | 234.19M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 127.01M | 115.87M | 258.39M | 243.43M |
| Total current liabilities | -- | -- | 6.61M | 8.58M | 6.67M | 9.44M |
| Short-term debt | -- | -- | 479.44K | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 214,236,927.00 | 214,703,000.00 | 8,274,000.00 | 11,069,000.00 |
| Total equity | -- | -- | -87.22M | -98.84M | 250.11M | 232.36M |
| Retained earnings | -- | -- | -92.18M | -104.73M | -118.55M | -138.41M |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -12.28M | -22.03M | -32.70M |
| Depreciation & amortization | 122.67K | 271.00K | 612.00K |
| Free cash flow | -12.49M | -24.02M | -33.49M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | -1.45M |
| Ending cash balance | 15.85M | 16.27M | 96.36M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.20M | -6.33M | -8.84M | -9.33M | -13.54M | -14.84M |
| Depreciation & amortization | 124.00K | 134.00K | 137.27K | 216.73K | 318.00K | 342.00K |
| Free cash flow | -8.37M | -6.38M | -8.99M | -9.75M | -14.22M | -16.77M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -1.45M | 0 | 0 | 160.43M | 0 |
| Ending cash balance | 58.00M | 127.24M | 106.01M | 96.36M | 238.90M | 223.14M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -- | -- | -- |
| ROA %i | -32.37 | -90.48 | -57.29 |
| ROIC %i | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -- | -- | -- |
| FCF / sales %i | -- | -- | -- |
| Current ratioi | 25.57 | 2.23 | 12.67 |
| Quick ratioi | 25.46 | 2.14 | 12.57 |
| Debt / assetsi | 0.00 | 16.71 | 1.37 |
| LT debt / equityi | -- | -- | -- |
| Interest coveragei | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -17.94 | -24.12 |
| ROA %i | -- | -- | -28.12 | -57.29 | -17.36 | -23.03 |
| ROIC %i | -- | -- | -- | -- | -19.64 | -26.54 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 18.11 | 12.67 | 38.00 | 25.06 |
| Quick ratioi | -- | -- | 17.92 | 12.57 | 37.75 | 24.89 |
| Debt / assetsi | -- | -- | 2.81 | 1.37 | 0.62 | 0.67 |
| LT debt / equityi | -- | -- | -- | -- | 0.64 | 0.70 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:03:04 · For reference only, not investment advice and not tailored to your situation.